Key facts
- This page summarizes Eric Crombez's Form 4 filing for Ultragenyx Pharmaceutical Inc. (RARE).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 06 May 2026, 14:51.
Eric Crombez - 05 May 2026 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)
- Reporting relationship
- EVP and Chief Medical Officer
- Issuer ticker
- RARE
- Reported as of
- 05 May 2026
- Net transaction value
- -$8,586
- SEC form
- 4
- Accepted by SEC
- 06 May 2026, 14:51:11 UTC
- Prior SEC filing
- 20 Apr 2026
- Next SEC filing
- 15 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Karah Parschauer, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Crombez filed Form 4 for Ultragenyx Pharmaceutical Inc. (RARE) on 06 May 2026.
Change
- Previous filing in this sequence was filed on 20 Apr 2026.
- Current net transaction value: -$8,586.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001653052
Primary reporting owner
Crombez Eric
- Relationship
- EVP and Chief Medical Officer
- Address
- C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO
- Signature
- /s/ Karah Parschauer, attorney-in-fact
- Signature date
- 06 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RARE
transaction
Common Stock
Sale
- Transaction value
- $8,586
- Shares
- -344
- Change %
- -0.31%
- Price
- $24.96
- Shares after
- 111,189
- Date
- 05 May 2026
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
Footnote F2
Includes 558 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2026
Footnote F3
Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.